Abstract
Background: During last years, DNA vaccine immunogenicity has been optimized by the employment of co-stimulatory molecules and molecular adjuvants. It has been reported that plasmid (pATRex), encompassing the DNA sequence for the von Willebrand A (vWA/A) domain of the Anthrax Toxin Receptor-1 (ANTXR-1, alias TEM8, Tumor Endothelial Marker 8), acts as strong immune adjuvant by inducing formation of insoluble intracellular aggregates. Markedly, we faced with upsetting findings regarding the safety of pATRex as adjuvant since the aggregosome formation prompted to osteopenia in mice.
Objective: The present study provides additional evidences about the proteinaceous adjuvants action within bone marrow and questioned regarding the self-aggregation protein adjuvants immunotoxicity on marrow niches.
Methods & Results: Using histological, biochemical and proteomic assays we shed light on pATRex effects within bone marrow niche and specifically we evidenced an aplastic-like bone marrow with disrupted cytokine/chemokine production.
Conclusion: The above findings provide compelling support to the thesis that adjuvants based on plasmids encoding protein aggregation domains disrupt the physiological features of the bone marrow elements.
Keywords: Bone marrow, Bone marrow niche, Osteopenia, DNA vaccines, Adjuvants, Protein aggregates.
Current Gene Therapy
Title:Molecular Adjuvants Based on Plasmids Encoding Protein Aggregation Domains Affect Bone Marrow Niche Homeostasis
Volume: 17 Issue: 5
Author(s): Maria Giovanna Sabbieti, Giovanna Lacava, Andrea Amaroli, Luigi Marchetti, Roberta Censi, Piera Di Martino and Dimitrios Agas*
Affiliation:
- School of Biosciences and Veterinary Medicine, University of Camerino, 62032 Camerino (MC),Italy
Keywords: Bone marrow, Bone marrow niche, Osteopenia, DNA vaccines, Adjuvants, Protein aggregates.
Abstract: Background: During last years, DNA vaccine immunogenicity has been optimized by the employment of co-stimulatory molecules and molecular adjuvants. It has been reported that plasmid (pATRex), encompassing the DNA sequence for the von Willebrand A (vWA/A) domain of the Anthrax Toxin Receptor-1 (ANTXR-1, alias TEM8, Tumor Endothelial Marker 8), acts as strong immune adjuvant by inducing formation of insoluble intracellular aggregates. Markedly, we faced with upsetting findings regarding the safety of pATRex as adjuvant since the aggregosome formation prompted to osteopenia in mice.
Objective: The present study provides additional evidences about the proteinaceous adjuvants action within bone marrow and questioned regarding the self-aggregation protein adjuvants immunotoxicity on marrow niches.
Methods & Results: Using histological, biochemical and proteomic assays we shed light on pATRex effects within bone marrow niche and specifically we evidenced an aplastic-like bone marrow with disrupted cytokine/chemokine production.
Conclusion: The above findings provide compelling support to the thesis that adjuvants based on plasmids encoding protein aggregation domains disrupt the physiological features of the bone marrow elements.
Export Options
About this article
Cite this article as:
Sabbieti Giovanna Maria , Lacava Giovanna , Amaroli Andrea , Marchetti Luigi , Censi Roberta , Di Martino Piera and Agas Dimitrios *, Molecular Adjuvants Based on Plasmids Encoding Protein Aggregation Domains Affect Bone Marrow Niche Homeostasis, Current Gene Therapy 2017; 17 (5) . https://dx.doi.org/10.2174/1566523218666180105122626
DOI https://dx.doi.org/10.2174/1566523218666180105122626 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endothelial Cell-Based Methods for the Detection of Cyanobacterial Anti- Inflammatory and Wound-Healing Promoting Metabolites
Drug Metabolism Letters The Tumor Stroma as Mediator of Drug Resistance - A Potential Target to Improve Cancer Therapy?
Current Pharmaceutical Biotechnology Targeting Antibody-Mediated Rejection in the Setting of ABOIncompatible Infant Heart Transplantation: Graft Accommodation vs. B Cell Tolerance
Current Drug Targets - Cardiovascular & Hematological Disorders Biological Aspects and Clinical Applications of Mesenchymal Stem Cells: Key Features You Need to be Aware of
Current Pharmaceutical Biotechnology Probiotics in Intestinal and Non-Intestinal Infectious Diseases – Clinical Evidence
Current Pharmaceutical Design Systems Biology Approaches in Identifying the Targets of Natural Compounds for Cancer Therapy
Current Drug Discovery Technologies MicroRNAs and Stem Cells to the Rescue
Current Neurovascular Research Clozapine Induced Eosinophilia in a Case of Schizoaffective Disorder
Current Psychopharmacology Lithium and Kidney, 60 Years Later
Current Drug Safety Preface [HotTopic: Cytokine Therapies for Diabetic Microvascular Complications (Executive Editor: J.L. Wilkinson-Berka)]
Current Pharmaceutical Design Editorial: [Hot Topic: Inflammation and Cancer: New Targets and Novel Therapeutic Approach]
Current Pharmaceutical Design S1P Regulation of Macrophage Functions in the Context of Cancer
Anti-Cancer Agents in Medicinal Chemistry Towards Cure of CML: Why We Need to Know More About CML Stem Cells?
Current Stem Cell Research & Therapy Endogenous Retroelements in Cellular Senescence and Related Pathogenic Processes: Promising Drug Targets in Age-Related Diseases
Current Drug Targets Molecular Imaging of Apoptosis In Vivo with Scintigraphic and Optical Biomarkers – A Status Report
Anti-Cancer Agents in Medicinal Chemistry Editorial [ Hot-topic: Molecularly Targeted Therapies in Breast Cancer Bone Metastases (Executive Editor: Philippe Clezardin)]
Current Pharmaceutical Design Simultaneous Determination of Cytochrome P450 Oxidation Capacity in Humans: A Review on the Phenotyping Cocktail Approach
Current Pharmaceutical Biotechnology Synthesis of Medicinally Privileged Heterocycles through Dielectric Heating
Current Medicinal Chemistry Matrix Metalloproteinase-9 and Airway Remodeling in Asthma
Current Drug Targets - Inflammation & Allergy Selective Inhibitors of Hepatitis B Virus Replication
Current Medicinal Chemistry - Anti-Infective Agents